Idaho Strategic Resources (AMEX:IDR) reported $2.36 million in sales this quarter. This is a 8.17 percent increase over sales of $2.18 million the same period last year.
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by summer 2024.
